ClinicalTrials.gg
RecruitingNCT06823609Updated Jan 13, 2026

Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors

A Phase 1 interventional study of QLS1304 tablet in Advanced Malignant Tumor, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in patients with advanced malignant solid tumors. This study was divided into two stages: dose escalation and dose expansion.

02

Conditions studied

  • Advanced Malignant Tumor
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteer to participate in this study, sign an form and have good compliance;
  • Age ≥ 18 years old, Male or female
  • score: 0-1
  • Expected survival ≥ 12 weeks
  • Local recurrent or advanced malignant solid tumor confirmed by histopathology or cytopathology;
  • Failed to standard treatment or has no standard treatment scheme;
  • Baseline presence of at least one evaluable lesion according to the v1.1;
  • The functional level of important organs is basically normal, meeting the requirements of the scheme
  • Female subjects with fertility and male subjects must agree to use highly effective during the study treatment period and within 180 days after the last medication;
  • Female subjects with fertility must have a negative serum HCG test within 7 days before the first medication in the study, and must be in non lactation.
  • Volunteer to participate in this clinical trial, willing and able to follow the procedures related to clinical visits and research, understand the research procedures, and have signed informed consent

Exclusion criteria

Exclusion Criteria:

  • 1. Subjects have received live or attenuated within 4 weeks before the first use of the drug.
  • Subjects have undergone major organ surgery within 4 weeks before the first use of the investigational drug.
  • Subjects require long-term or high-dose use of non-steroidal drugs.
  • Subjects have not recovered from adverse events (AEs) caused by previous anti-tumor treatment to ≤ grade 1.
  • Subjects have a known or suspected severe allergy to theinvestigational drug or any of its components Subjects have other active malignant tumors within 5 years before the first use of the investigational drug.
  • Subjects have and/or carcinomatous meningitis or .
  • Subjects have active tuberculosis, radiation pneumonitis, drug-induced pneumonitis, pulmonary fibrosis, or other diseases, symptoms, or signs of severe lung function impairment.
  • Subjects are unable to swallow tablets or had gastrointestinal abnormalities that the investigator assessed as potentially affecting drug absorption.
  • Subjects have a history of severe cardiovascular or cerebrovascular disease within 6 months before the first use of the investigational drug.
  • Subjects have a hypertension medial history that blood is not well controlled despite treatment with multiple antihypertension drugs.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    QLS1304 tablet

    Drug: QLS1304 tablet

Interventions

  • DrugQLS1304 tablet

    QLS1304 monotherapy dose escalation and expansion

06

What researchers measure

Primary outcomes

  1. Dose limited toxicity (DLT) of QLS1304

    Time frame: up to 35 days

  2. Maximum tolerated dose(MTD)of QLS1304

    Time frame: up to 35 days

  3. Recommended Phase II Dose (RP2D) of QLS1304

    Time frame: up to 35 days

Secondary outcomes

  1. adverse event

    Time frame: from the first drug administration to within 30 days for the last treatment dose

  2. Cmax

    Time frame: through study completion, an average of 2 year

  3. objective response rate(ORR)

    Time frame: through study completion, assessed up to 24 months

  4. Tmax

    Time frame: through study completion, an average of 2 year

  5. AUC0-t

    Time frame: through study completion, an average of 2 year

  6. AUC0-inf

    Time frame: through study completion, an average of 2 year

  7. CL/F

    Time frame: through study completion, an average of 2 year

  8. Vd/F

    Time frame: through study completion, an average of 2 year

  9. MRT

    Time frame: through study completion, an average of 2 year

  10. t1/2

    Time frame: through study completion, an average of 2 year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2025
First posted
Feb 12, 2025
StartActual
Mar 6, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06823609
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Mar 6, 2025
Primary completion
Nov 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion